Italy is a top-three EU country for R&D in pharmacology, toxicology, and pharmaceutical research and clinical trials.
Milano is one of the largest centers for pharmaceutical and medical device clinical trials, with a particular focus on rare diseases, orphan drugs and a strong pipeline of drug candidates. 2 out of 10 advanced clinical trials approved in the EU are Italian.
The city represents 28% of the Italian biotech sector and boasts a rich network of academia, research organizations, national and international regulators, government and complementary industries, which provide a unique breeding ground for science, research, and innovation.
30% of the total inward FDIs in Italy are directed to Milano. 5,300 multinationals (47% of the national total) employ over 420,000 people.
Thanks to its deeply-rooted entrepreneural fabric, 11 top-ranked universities, 347,000 Life Sciences employees, 130,000 skilled healthcare workers and state of the art research hospitals (IRCCS), Milano is already home to >250 biotech companies, Life Science trade bodies, and Human Technopole, Italy’s new research istitute for Genomics and Computational Biology based at MIND – Milano Innovation District. Prestigious international accelerators such as Berkeley Skydeck have chosen the city to expand internationally with the exciting launch of Berkeley Skydeck Europe @MIND. The District will soon inaugurate Galezzi Hospital’s (18th worldwide for Orthopedics) 600 bed facility.